RxDoctor Payments Data

Clinton McMahill, MD

Internal Medicine · Lander, WYNPI 1245556190

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 5 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by Medtronic at 59.3% of the total. Reporting peaked in 2022 at $56 and has fallen 70.9% since, to $16 in 2024.

$95in general payments, 2019–2025

Across 5 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$56
  • Sunovion Pharmaceuticals Inc.$22
  • AstraZeneca$16

What the payments were for

  • Food & beverage$95100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$95 in reported general payments places this provider in the 55th percentile of 101 internal medicine providers in Wyoming.

See all internal medicine providers in Wyoming

Medicare billing

Part B allowed, 2024
$398,232
Medicare patients
767
Services billed
8,066

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban193$134,752
OzempicSemaglutide121$125,889
Humira(Cf) PenAdalimumab11$70,043
XareltoRivaroxaban56$54,001
JardianceEmpagliflozin46$51,207
MounjaroTirzepatide33$32,245
JanuviaSitagliptin Phosphate66$31,176
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$25,423
FarxigaDapagliflozin Propanediol47$25,147
Tresiba Flextouch U-100Insulin Degludec24$17,661
MyrbetriqMirabegron51$15,712
TrulicityDulaglutide16$14,743
Tresiba Flextouch U-200Insulin Degludec14$12,412
Humalog Kwikpen U-100Insulin Lispro29$11,584
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog19$9,212

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$16$33,93161 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 101 internal medicine providers in Wyoming.

Other internal medicine in Lander

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →